查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
尿路感染治疗市场：按药物、适应症、地区划分——规模、份额、展望、机会分析，2022-2028 年
市场调查报告书
商品编码
1149888

尿路感染治疗市场：按药物、适应症、地区划分——规模、份额、展望、机会分析，2022-2028 年

Urinary Tract Infection Therapeutic Market, By Drug, By Indication, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
出版日期: | 出版商: Coherent Market Insights | 英文 197 Pages | 商品交期: 2-3个工作天内

价格
简介目录

尿路感染 (UTI) 是一种影响泌尿系统任何部分的感染。与男性相比，女性患尿路感染的风险更高。尿路感染 (UTI) 通常是由粪便中的细菌进入尿路引起的。通常首先使用抗生素治疗尿路感染。单纯性尿路感染常用药物有甲氧芐氨嘧啶磺胺甲噁唑（Bactrim、Bactrim DS）、磷霉素（Monurol）、夫喃妥因（Macrodantin、Macrobid、Furadantin）、头孢氨芐、ceftoria Kison等。

市场动态。

尿路感染的高患病率、糖尿病和肾结石患病率的上升、老年人口的增加、对开发新疗法的日益关注等将在预测期内推动全球尿路感染治疗市场。是其中之一预计推动增长的主要因素

2021 年 10 月，Spero Therapeutics, Inc. 寻求美国食品和药物管理局 (FDA) 批准替比培南 HBr 片剂用于治疗复杂性尿路感染 (cUTI)，包括易感微生物引起的肾盂肾炎。药物申请 (NDA) 已提交给美国食品和药物管理局。此外，2021年9月，BDR Pharma推出了用于腹腔内感染、下呼吸道感染和復杂尿路感染患者的比阿培南。

2019年7月，美国食品药品监督管理局（FDA）批准抗菌药物利卡比南（亚胺培南、西司他丁、瑞巴坦）已获批。

这项研究的主要特点

  • 本报告对全球尿路感染治疗市场进行了深入分析，提供了以 2021 年为基准年的预测期（2022-2028 年）的市场规模和復合年增长率 (CAGR%)。
  • 它还阐明了各个细分市场的潜在创收机会，并描述了针对该市场的一系列有吸引力的投资建议。
  • 它还提供有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
  • 它根据以下参数（包括公司亮点、产品组合、主要亮点、绩效和战略）介绍了全球尿路感染治疗市场的主要参与者。
  • 参与这项研究的主要公司包括辉瑞、诺华、西普拉、拜耳、阿斯利康、盐野义和葛兰素史克。
  • 这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。我猜。
  • 《全球尿路治疗市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
  • 利益相关者将能够通过用于分析全球尿路感染治疗市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

  • 调查目的
  • 先决条件
  • 缩写说明

第二章市场展望

  • 报告内容
    • 市场定义和范围
  • 执行摘要
    • 尿路感染治疗市场：按药物分类
    • 尿路感染治疗市场：按适应症分类
    • 尿路感染治疗市场：按地区
  • 连贯机会图 (COM)

第3章市场动态、规律及趋势分析

  • 市场动态
    • 全世界尿路感染的高发率
    • 与使用尿路感染治疗相关的副作用
    • 越来越关注新药开发
  • 影响分析
  • 主要亮点
  • 监管情景
  • 产品发布/批准
  • 害虫分析
  • 对 PORTER 的分析
  • 合併/收购场景

第 4 章全球尿路感染治疗市场：冠状病毒 (COVID-19) 大流行的影响

  • COVID-19 的流行病学特征
  • 供应方和需求方分析
  • 经济影响

第 5 章全球尿路感染治疗市场：按药物分类，2017-2028

  • 青霉素和伴随药物
  • 奎诺酮类
  • 头孢类
  • 唑和两性霉素 B
  • 硝基夫喃
  • 其他药物

第 6 章全球尿路感染治疗市场：按适应症分类，2017-2028

  • 复杂性尿路感染
  • 非全身性尿路感染
  • 其他适应症

第 7 章全球尿路感染治疗市场：按地区划分，2017-2028

  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲
  • 世界其他地方

第八章竞争格局

  • Pfizer
  • Novartis AG
  • Cipla Inc.
  • Bayer AG
  • AstraZeneca
  • Shionogi & Co. Ltd.
  • GlaxoSmithKline PLC

第 9 章

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI1178

A urinary tract infection (UTI) is an infection in any part of the urinary system. Women are at greater risk of developing a urinary tract infection compared to men. Urinary tract infections (UTIs) are usually caused by bacteria from poo entering the urinary tract. Antibiotics usually are the first treatment for urinary tract infections. Medicines commonly used for simple UTI s include Trimethoprim and sulfamethoxazole (Bactrim, Bactrim DS), Fosfomycin (Monurol), Nitrofurantoin (Macrodantin, Macrobid, and Furadantin), Cephalexin, and Ceftriaxone.

Market Dynamics:

High prevalence of urinary tract infection, increasing prevalence of diabetes and kidney stones, increasing geriatric population, and increase in focus on the development of novel therapeutics are some major factors expected to drive growth of the global urinary tract infection therapeutic market during the forecast period.

In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the U.S. Food and Drug Administration (USFDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms. Moreover, in September 2021, BDR Pharma launched biapenem for the treatment of patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.

In July 2019, the U.S. Food and Drug Administration (FDA) approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

Key features of the study:

  • This report provides in-depth analysis of the global urinary tract infection therapeutic market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global urinary tract infection therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global urinary tract infection therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urinary tract infection therapeutic market.

Detailed Segmentation:

  • Global Urinary Tract Infection Therapeutic Market By Drug:
    • Penicillin and Combinations
    • Quinolones
    • Cephalosporin
    • Azoles and Amphotericin B
    • Nitrofurans
    • Other Drugs
  • Global Urinary Tract Infection Therapeutic Market By Indication;
    • Complicated UTI
    • Uncomplicated UTI
    • Other Indications
  • Global Urinary Tract Infection Therapeutic Market By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • Pfizer
    • Novartis AG
    • Cipla Inc.
    • Bayer AG
    • AstraZeneca
    • Shionogi & Co. Ltd.
    • GlaxoSmithKline PLC

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Urinary Tract Infection Therapeutic, By Drug
    • Market Urinary Tract Infection Therapeutic, By Indication
    • Market Urinary Tract Infection Therapeutic, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • High prevalence of urinary tract infection across the globe
    • Adverse effects associated with the use of UTI medication
    • Increase in focus on the development of novel drugs
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Urinary Tract Infection Therapeutic Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Urinary Tract Infection Therapeutic Market, By Drug, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Penicillin and Combinations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Quinolones
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Cephalosporin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Azoles and Amphotericin B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Nitrofurans
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Other Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Global Urinary Tract Infection Therapeutic Market, By Indication, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Complicated UTI
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Uncomplicated UTI
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Other Indications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

7. Global Urinary Tract Infection Therapeutic Market, By Geography, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Middle East and Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Rest of World
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

8. Competitive Landscape

  • Pfizer
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Cipla Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Shionogi & Co. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline PLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us